Zhitong Finance App News, Harbin Pharmaceutical Co., Ltd. (600664.SH) issued an announcement. Recently, the company's subsidiary Harbin Pharmaceutical Group Bioengineering Co., Ltd. (“Harbin Pharmaceutical Biology”) received the “Notice of Approval of the Marketing Application for Chemical Ingredients” [ID: 2026YS00706] for potassium sulfate issued by the State Drug Administration. Potassium sulfate is one of the raw materials for oral administration of concentrated magnesium, sodium, and potassium sulfate, and exerts an osmotic laxative effect. This product has obtained a notice of approval for the marketing application of a chemical raw material, indicating that the API has met the relevant national drug evaluation technical standards.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.